Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Exploration and Practice of Medicine Pathway for Perioperative VTE Prophylactic Anticoagulant Treatment

Author(s): Bin Zhang, Chuanzhou Zhang, Yongxin Li, Changkai Zhou, Shiqiang Shi, Hongyan Ji and Jing Li*

Volume 29, Issue 4, 2023

Published on: 20 January, 2023

Page: [251 - 255] Pages: 5

DOI: 10.2174/1381612829666230112165449

Price: $65

conference banner
Abstract

Objective: Using perioperative VTE prophylactic anticoagulant pathway delicacy management, we aimed to explore the role of clinical pharmacists in perioperative VTE prophylactic anticoagulant treatment and the effect of the clinical medicine pathway implementation.

Methods: In compliance with evidence-based medicine, combined with clinical practice, clinical pharmacists participated in the formulation of the perioperative anticoagulant clinical medicine pathway. The PDCA cycle was strictly implemented. Urologic Department, Affiliated Hospital of Qingdao University, Qingdao Shandong, China, served as a pilot department for the evaluation of the effect of drug clinical pathway implementation.

Results: The anticoagulant clinical medicine pathway for the urologic department was formulated and implemented from October 2020 to August 2021. The entry rate gradually increased, and the accuracy of thrombosis risk assessment improved. The proportion of drugs in the department and the per capita drug cost decreased significantly.

Conclusion: The perioperative VTE prophylactic anticoagulant pathway showed significant achievements in the rational use of urologic anticoagulant drugs, lowering the cost of medical care. Therefore, it could be considered a novel long-term mechanism for rational analgesia drug use.

Keywords: Anticoagulant, clinical medicine pathway, urologic, perioperative, VTE, rational drug use.

« Previous Next »
[1]
Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6): 381S-453S.
[2]
Liang Y, Meng Z, Zhou CK, et al. Exploration and practice of clinical medicine pathway of proton pump inhibitors during perioperative period. China Pharmaceuticals 2020; 29: 33-6.
[3]
Moscoso MB, Mottier D, Nonent M, et al. Diagnosis of postoperative venous thromboembolism. Presse Med 2003; 32(18): 852-9.
[4]
Saucier A, Huang EY, Emeremni CA, Pershad J. Prospective evaluation of a clinical pathway for suspected appendicitis. Pediatrics 2014; 133(1): e88-95.
[http://dx.doi.org/10.1542/peds.2013-2208]
[5]
Jing FB, Zhou CK, Han B, et al. Exploration and practice of clinical medicine pathway in the hospital. Chin Hospital Manag 2019; 39: 4.
[6]
Chinese Guidelines for the prevention and treatment of thrombotic diseases. Nat Med J China 2018; 98: 2861-88.
[7]
Zhang K, Zhai MY. Chinese urology perioperative thrombosis prevention and management expert consensus. J Modern Urol 2018; 25: 1048-51.
[8]
Zhou CK, Ding SM, Zhang R, et al. Establishment of management model for rational drug use based upon PDCA cycles and clinical medication pathway. Zhongguo Yiyuan Yaoxue Zazhi 2021; 41: 98-102.
[9]
Ma L, Feng BL, Wang JP, et al. Effect of PDCA Cycle on multidisciplinary collaborative management of carbapenems. China Pharmaceuticals 2021; 30: 15-7.

Rights & Permissions Print Cite
Article Metrics
52
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy